Back

Red cell distribution width as a predictor of cardiovascular events in high-risk patients with statin intolerance: post-hoc analysis of the CLEAR Outcomes trial

1 September 2024 (08:25 - 08:35)
Organised by: Logo
Congress Presentation Part of: The broad spectrum of cardiovascular risk Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Patrick Moriarty

University of Kansas Medical Center, Kansas City (United States of America)

5 More presentations in this session

Presentation thumbnail
Heterogeneous effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular events among people with type 2 diabetes: an application of machine learning to target trial emulation
Doctor Y. Mori (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
High physical activity relates to higher risk of incident carotid plaque components
Mr L. Zuo (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Estimation of individual lifetime cardiovascular disease risk and treatment benefit in patients with established atherosclerotic cardiovascular disease: the updated SMART-REACH2 model
Mr J. Holtrop (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Sex-differences in prescription patterns of secondary prevention pharmacotherapy in patients with acute myocardial infarction: a 20-year perspective
Professor H. Rickli (St. Gallen, CH)
Abstract Slides Video
Presentation thumbnail
Association of insulin resistance with cardiovascular disease and all-cause mortality in type 1 diabetes mellitus: systematic review and meta-analysis
Doctor R. Sun (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
The broad spectrum of cardiovascular risk
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 08:25 CET
You may be interested in
thumbnail
Congress Session
Clinical trial updates on prevention and lipid lowering
thumbnail
Congress Presentation
Omecamtiv mecarbil and red cell distribution width in patients with heart failure and reduced ejection fraction: results from the GALACTIC-HF trial
thumbnail
Congress Presentation
CLEAR - Outcomes total events analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources